Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Kidney problems news

Show

From To
Two-drug maintenance therapy keeps viral load suppressed and may even have advantages over traditional ART

Two-drug antiretroviral therapy (ART) consisting of ritonavir-boosted atazanavir and lamivudine has comparable or better virological efficacy than traditional three-drug therapy based on ritonavir/atazanavir, according to a poster presentation at

Published
30 November 2015
By
Michael Carter
NIH publishes criteria for research on organ transplantation between people with HIV infection

​In a Federal Register notice on Nov. 25, 2015, the U.S. Department of Health and Human Services published safeguards and criteria for research to assess the safety and effectiveness of solid organ transplantation from donors with HIV infection to recipients with HIV infection.

Published
27 November 2015
From
National Institutes of Health
Benefits of early HIV treatment are clear, but issues raised by START and D:A:D remain unresolved

The long-running controversy over when to start antiretroviral therapy (ART) has been definitively answered, but research is still needed to fully understand the implications of the large START

Published
23 October 2015
By
Liz Highleyman
Studies continue to support tenofovir alafenamide combination pill as it nears US approval

A single-tablet regimen containing a new formulation of tenofovir maintained viral suppression for people switching from other combinations and was associated with improved kidney function and bone health,

Published
19 October 2015
By
Liz Highleyman
TAF and TDF Compared for Kidney, Bone Toxicity in Black HIV+ Patients

Including tenofovir alafenamide (TAF) in single-tablet elvitegravir/cobicistat/emtricitabine (E/C/F/TAF) is associated with reduced renal and bone toxicity compared to tenofovir disoproxil fumarate (TDF)-containing single-tablet (E/C/F/TDF) therapy, according to an analysis of data from two Phase 3 trials, reported at IDWeek 2015.

Published
12 October 2015
From
Monthly Prescribing Reference
High standards of care associated with reduced mortality risk of patients with HIV

Quality of care (QOC) in the first twelve months after entering HIV care is associated with longer-term mortality risk, investigators from the US Department of Veterans Affairs report

Published
28 September 2015
By
Michael Carter
Tenofovir Alafenamide Combo Pill Matches Truvada for HIV Efficacy, but Easier on Bones and Kidneys

A fixed-dose combination pill containing tenofovir alafenamide (TAF) worked as well in a Phase 3 trial as the current Truvada pill containing the older tenofovir disoproxil fumarate (TDF) -- which is used for both HIV treatment and pre-exposure prophylaxis or PrEP -- but causes less kidney and bone toxicity, according to an announcement this week from Gilead Sciences.

Published
04 September 2015
From
HIVandHepatitis.com
Switching to new tenofovir alafenamide keeps virus in check and improves kidney and bone health

People who switch from the current version of tenofovir to tenofovir alafenamide (TAF) – a new formulation that reaches higher levels in HIV-infected cells – maintained undetectable

Published
28 July 2015
By
Liz Highleyman
Geriatric HIV: living with multiple medical conditions will become the norm as population ages

In fifteen years' time, the clinical needs of Dutch people living with HIV will have changed substantially due to three quarters of them being over the

Published
16 June 2015
By
Roger Pebody
Lower daily tenofovir dose of 150mg safe and effective in people with moderate renal impairment

A reduced tenofovir (Viread) dose of 150mg daily appears to be a safe and effective treatment for people with HIV who have moderate renal impairment, investigators from

Published
22 May 2015
By
Michael Carter
← First12345...10Next →

Filter by country